The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
- Investigator
- Ginger Clark
- Ages
- 18 Years - 75 Years
- Sexes
- All